Wednesday, 2 July 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 02 July 2025
News

AZ pulls breast cancer drug

Posted 30 June 2025 AM

AstraZeneca has pulled its long-standing breast cancer treatment Faslodex from the Australian market as three companies, including the UK pharma giant itself, inch closer to commercialising their next generation medicines.

Faslodex, which is administered via an intramuscular injection was the only Selective Estrogen Receptor Degrader (SERD) available up until around 2020 when generic versions of the drug started to trickle onto the ARTG before being listed on the PBS from March 2021 onwards.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (10)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (1)

Devices (1)

Other (10)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.